Clinical Trials Logo

Herpes Simplex 1 clinical trials

View clinical trials related to Herpes Simplex 1.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06135844 Recruiting - Virus Clinical Trials

Hand Sanitizer Use for Herpes Simplex Virus-1

Start date: April 8, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of this pilot study is to determine if the use of Purell hand sanitizer alters the duration, level of pain and discomfort during treatment, and the size of the HSV-1 lesion. The duration of an HSV-1 (herpes) lesion is the primary endpoint for this study. Size, pain, and discomfort are the secondary endpoints.

NCT ID: NCT05823779 Recruiting - HIV Disease Clinical Trials

A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects

HSVHIV
Start date: April 1, 2022
Phase:
Study type: Observational

This study is an observational, cohort, prospective study looking at the frequency of Herpes Simplex Virus (HSV) 1 and or 2 outbreaks in HIV positive patients who's HIV virus is controlled on highly active anti-retroviral therapy. We will be enrolling fifty (50) patients.

NCT ID: NCT05198570 Recruiting - Oncology Clinical Trials

Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients

Start date: September 15, 2021
Phase:
Study type: Observational

- Herpesvirus infections may be severe in immunocompromised patients, with a high risk of complications and mortality. - Recipients of hematopoietic stem cell transplant (HSCT) or patients receiving high-intensity chemotherapy for hematological malignancies are the most vulnerable individuals. - Although the worldwide prevalence of herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV), antiviral prophylaxis in seropositive HSCT recipients has significantly reduced the rate of infection. - Acyclovir (ACV) is the first-choice drug for the prophylaxis or the therapy of that kind of infection. - Since the beginning, ACV has demonstrated to be characterized by a large interpatient variability, especially in children. - Therefore, therapeutic drug monitoring and pharmacokinetic studies may help in optimizing drug in children with malignancies.